Studi Literatur Pengembangan Sediaan Mucoadhesive Drug Delivery System (MDDS) untuk Penghantaran Metformin Hidroklorida
DOI:
https://doi.org/10.29313/bcsp.v3i2.8874Keywords:
Kata Kunci: Mucoadhesive drug delivery system, Metformin HCl, Bioavailabilitas., Keywords: Mucoadhesive drug delivery system, Metformin HCl, Bioavailabilitas.Abstract
Abstrak. Metformin HCl memiliki beberapa masalah seperti bioavailabilitas yang rendah, waktu paruh yang pendek dan jendela penyerapan yang sempit, sehingga perlu dikembangkan sistem penghantaran obat yang berkelanjutan untuk mengatasi keterbatasan tersebut. Mucoadhesive Drug Delivery System (MDDS) adalah sistem yang mampu mengikat permukaan sel epitel lambung, sehingga berfungsi sebagai sarana potensial untuk memperpanjang retensi di lambung dengan meningkatkan durasi kontak obat dengan membran biologis. Penelitian ini bertujuan untuk menentukan formula optimum serta pengaruhnya terhadap nilai AUC dan bioavailabilitas. Metode penelitian yang digunakan yaitu systematic literatur review dengan cara mencari artikel internasional dari penerbit bereputasi. Hasil penelitian ini menunjukan bahwa sediaan MDDS yang sudah dikembangkan untuk zat aktif metformin HCl telah memuhi persyaratan sediaan yang baik karena memiliki waktu mukoadhesif yang optimum (>6 jam). Selain itu, sediaan MDDS ini mampu meningkatkan nilai bioavailabilitas serta AUC dari metformin HCl dalam rentang 65 – 113%. Sediaan MDDS dapat dijadikan solusi untuk perbaikan efektivitas pengobatan dari zat aktif metformin HCl dalam tubuh dengan pengujian yang lebih lanjut.
Abstract. Metformin HCl has several problems such as low bioavailability, short half-life and narrow absorption window, so it is necessary to develop a sustainable drug delivery system to overcome these limitations. Mucoadhesive Drug Delivery System (MDDS) is a system capable of binding to the surface of gastric epithelial cells, thereby functioning as a potential means to extend retention in the stomach by increasing the duration of drug contact with biological membranes. This study aims to determine the optimum formula and its effect on AUC values and bioavailability. The research method used is systematic literature review by searching for international articles from reputable publishers. The results of this study indicate that the MDDS preparation that has been developed for the active substance metformin HCl has met the requirements of a good preparation because it has an optimum mucoadhesive time (> 6 hours). In addition, this MDDS preparation was able to increase the bioavailability and AUC values of metformin HCl in the range of 65 – 113%. MDDS preparations can be used as a solution to improve the effectiveness of the treatment of the active substance metformin HCl in the body with further testing.
References
[2] K. Khunti et al., “Design and rationale of DISCOVER global registry in type 2 diabetes: Real-world insights of treatment patterns and its relationship with cardiovascular, renal, and metabolic multimorbidities,” J. Diabetes Complications, vol. 35, no. 12, p. 108077, 2021, doi: 10.1016/j.jdiacomp.2021.108077.
[3] F. G. Senjoti, S. Mahmood, J. M. Jaffri, and U. K. Mandal, “Design and In-vitro evaluation of sustained release floating tablets of metformin HCl based on effervescence and swelling,” Iran. J. Pharm. Res., vol. 15, no. 1, pp. 53–70, 2016.
[4] M. Metry et al., “Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Metformin Hydrochloride,” J. Pharm. Sci., vol. 110, no. 4, pp. 1513–1526, 2021, doi: 10.1016/j.xphs.2021.01.011.
[5] B. Kim, Y. Byun, and E. H. Lee, “Doe-based design of a simple but efficient preparation method for a non-effervescent gastro-retentive floating tablet containing metformin hcl,” Pharmaceutics, vol. 13, no. 8, 2021, doi: 10.3390/pharmaceutics13081225.
[6] F. Khonsari, P. Zakeri-Milani, and M. Jelvehgari, “Formulation and evaluation of in-vitro characterization of gastic- mucoadhesive microparticles/discs containing metformin hydrochloride,” Iran. J. Pharm. Res., vol. 13, no. 1, pp. 67–80, 2014.
[7] R. Malik, T. Garg, A. K. Goyal, and G. Rath, “Polymeric nanofibers: Targeted gastro-retentive drug delivery systems,” J. Drug Target., vol. 23, no. 2, pp. 109–124, 2015, doi: 10.3109/1061186X.2014.965715.
[8] S. Khalid et al., “Thiolated sodium alginate conjugates for mucoadhesive and controlled release behavior of metformin microspheres,” Int. J. Biol. Macromol., vol. 164, pp. 2691–2700, 2020, doi: 10.1016/j.ijbiomac.2020.08.116.
[9] M. Jelvehgari, P. Zakeri-Milani, and F. Khonsari, “Comparative study of in vitro release and mucoadhesivity of gastric-compacts composed of multiple unit system/bilayered discs using direct compression of metformin hydrochloride,” BioImpacts, vol. 4, no. 1, pp. 29–38, 2014, doi: 10.5681/bi.2014.002.
[10] A. N. Allam, S. S. El gamal, and V. F. Naggar, “Bioavailability : A Pharmaceutical Review Bioavailability,” Nov. Drug Deliv Tech, vol. 1, no. 1, pp. 77–93, 2011.
[11] M. Manconi et al., “Improving oral bioavailability and pharmacokinetics of liposomal metformin by glycerolphosphate-chitosan microcomplexation,” AAPS PharmSciTech, vol. 14, no. 2, pp. 485–496, 2013, doi: 10.1208/s12249-013-9926-4.
[12] J. Piao, J. E. Lee, D. H. Shin, and J. S. Kim, “Pharmacokinetic study of mucoadhesive metformin pellets in rats,” J. Pharm. Investig., vol. 42, no. 3, pp. 133–137, 2012, doi: 10.1007/s40005-012-0019-2.
[13] M. Razavi et al., “Gastroretentive behavior of orally administered radiolabeled tamarind seed formulations in rabbits validated by gamma scintigraphy,” Drug Des. Devel. Ther., vol. 11, pp. 1–15, 2017, doi: 10.2147/DDDT.S115466.
[14] A. Nasution, Farmakokinetika Klinis. 2015.
